Jeffrey Ubben’s ValueAct Continues to Surge Despite its Valeant Stake

July 14, 2017   Stephen Taub


The activist firm’s flagship hedge fund is still up for the year despite still holding shares of the embattled drugmaker.

Who says you can’t make money if you are all in on Valeant Pharmaceuticals International? While hedge funds managed by Bill Ackman’s Pershing Square Capital Management and John Paulson’s Paulson & Company have suffered sharp losses in the past year …

Subscribe

Subscribers have unlimited access to all online content inc rankings. Start your subscription today - click on the button below.

Subscribe now

Free trial

Taking a free trial will give you access to online content one week (excludes research & rankings). Start your trial today.

Free Trial




Latest Poll

How will hedge funds finish 2017?

 - 73%
 - 12%
 - 15%

View previous results